Drugs & TargetsFree Rubicon Genomics Inc. extends its clinical supply agreement with Agendia April 10, 2015Vol.41 No.14
Drugs & TargetsFree Intrexon Corp. signs cooperative research and development agreement with NCI April 10, 2015Vol.41 No.14
Drugs & Targets Intrexon Corporation and Merck Serono to collaborate on CAR-T cancer therapies April 03, 2015Vol.41 No.13
Drugs & Targets Merck and Syndax Pharmaceuticals to evaluate combination of Keytruda and entinostat April 03, 2015Vol.41 No.13
Drugs & Targets Eli Lilly and OncoMed Pharmaceuticals to evaluate combination of demcizumab and Alimta April 03, 2015Vol.41 No.13
Drugs & Targets MD Anderson Cancer Center and Astellas Pharma Inc. sign option agreement for AML research April 03, 2015Vol.41 No.13
Drugs & Targets FDA Approves Chelator Jadenu, an Oral Formulation of Exjade April 03, 2015Vol.41 No.13
Drugs & Targets FDA updates label for Zytiga plus prednisone in metastatic castration-resistant prostate cancer April 03, 2015Vol.41 No.13
Drugs & Targets FDA Grants Accelerated Approval to Farydak For Patients with Multiple Myeloma March 31, 2015Vol.38 No.03
